Omda AS

DB:6Q1 Stock Report

Market Cap: €49.2m

Omda Valuation

Is 6Q1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6Q1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6Q1 (€2.64) is trading below our estimate of fair value (€9.17)

Significantly Below Fair Value: 6Q1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6Q1?

Key metric: As 6Q1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6Q1. This is calculated by dividing 6Q1's market cap by their current earnings.
What is 6Q1's PE Ratio?
PE Ratio6.3x
EarningsNOK 90.51m
Market CapNOK 572.68m

Price to Earnings Ratio vs Peers

How does 6Q1's PE Ratio compare to its peers?

The above table shows the PE ratio for 6Q1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.9x
M3V MeVis Medical Solutions
7.7xn/a€44.4m
AJ91 DocCheck
16.9xn/a€41.4m
COP CompuGroup Medical SE KGaA
30.8x32.9%€775.0m
NXU Nexus
44.1x17.1%€1.2b
6Q1 Omda
6.3x-32.9%€572.7m

Price-To-Earnings vs Peers: 6Q1 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (24.9x).

Price to Earnings Ratio vs Industry

How does 6Q1's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6Q1 6.3xIndustry Avg. 18.2xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6Q1 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the European Healthcare Services industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is 6Q1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6Q1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.3x
Fair PE Ratio7.2x

Price-To-Earnings vs Fair Ratio: 6Q1 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6Q1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.64
€3.77
+42.6%
20.5%€4.54€3.00n/a2
Nov ’25€2.70
€3.53
+30.7%
16.7%€4.12€2.94n/a2
Oct ’25€2.67
€3.73
+39.6%
10.1%€4.10€3.35n/a2
Sep ’25€3.17
€4.06
+28.0%
14.0%€4.62€3.49n/a2
Aug ’25€3.55
€4.06
+14.3%
14.0%€4.62€3.49n/a2
Jul ’25€2.95
€4.06
+37.5%
14.0%€4.62€3.49n/a2
Jun ’25€2.88
€4.30
+49.3%
18.4%€5.09€3.51n/a2
May ’25€2.87
€4.22
+46.9%
18.4%€4.99€3.44n/a2
Apr ’25€2.68
€4.22
+57.3%
18.4%€4.99€3.44n/a2
Mar ’25€2.25
€4.80
+113.3%
26.6%€6.08€3.52n/a2
Feb ’25€2.94
€4.71
+60.3%
27.9%€6.03€3.40n/a2
Jan ’25€3.35
€4.71
+40.7%
27.9%€6.03€3.40n/a2
Dec ’24€3.26
€4.71
+44.6%
27.9%€6.03€3.40n/a2
Nov ’24€2.47
€4.95
+100.4%
9.4%€5.42€4.48€2.702
Oct ’24€2.82
€5.09
+80.4%
9.4%€5.57€4.61€2.672
Sep ’24€3.41
€5.13
+50.3%
10.2%€5.65€4.60€3.172
Aug ’24€3.67
€5.08
+38.5%
8.3%€5.50€4.66€3.552
Jul ’24€3.69
€5.08
+37.7%
8.3%€5.50€4.66€2.952
Jun ’24€3.82
€5.08
+33.0%
8.3%€5.50€4.66€2.882
May ’24€3.27
€5.00
+52.9%
20.4%€6.02€3.98€2.872
Apr ’24€3.30
€5.00
+51.5%
20.4%€6.02€3.98€2.682
Mar ’24€3.08
€5.17
+68.0%
20.4%€6.23€4.12€2.252
Feb ’24€3.28
€5.37
+63.8%
20.4%€6.46€4.28€2.942
Jan ’24€3.73
€5.37
+44.0%
20.4%€6.46€4.28€3.352
Dec ’23€3.94
€5.93
+50.6%
17.4%€6.96€4.90€3.262

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%